Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PProteomic analysis of enhanced cellular effects of electroporation and cisplatin in triple-negative breast cancer cells

ABSTRACT: We performed a comprehensive and label-free quantitative proteomic analysis of the human adenocarcinoma epithelial TNBC cells (MDA-MB-231) treated with Cisplatin (CsP) and Cisplatin with EP (EP+CsP). We identified hundreds of differentially expressed proteins that defines molecular mechanisms involved in cellular responses of MDA-MB-231 cells to ECT. The underlying dataset represents a valuable resource for mechanistic studies and for the validation of knowledge gained from this study in the future using animal models. The systemic data should build a foundation for a better understanding of the mechanisms of the cytotoxicity of the Cisplatin as a potent anticancer drug.

INSTRUMENT(S): Q Exactive Orbitrap HF mass spectrometer

ORGANISM(S): Mda-mb-231 Tnbc Model Cells

SUBMITTER: Rajeswari Sundararajan

PROVIDER: MSV000083360 | MassIVE | Thu Jan 24 14:07:00 GMT 2019

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data from MDA-MB-231 parental and xenograft tumor cells treated with Smac mimetic SM-164.

Project description:Small-molecule Smac mimetics target inhibitor of apoptosis (IAP) proteins to induce TNFÎ±-dependent apoptosis in cancer cells and several Smac mimetics have been advanced into clinical development as a new class of anticancer drugs. However, preclinical studies have shown that only a small subset of cancer cell lines are sensitive to Smac mimetics used as single agents and these cell lines are at risk of developing drug resistance to Smac mimetics. Thus, it is important to understand the molecular mechanisms underlying intrinsic and acquired resistance of cancer cells to Smac mimetics in order to develop effective therapeutic strategies to overcome or prevent Smac mimetic resistance. We established Smac mimetic resistant sublines derived from MDA-MB-231 breast cancer cells, which exhibit exquisite sensitivity to the Smac mimetic SM-164, and used microarrays to detail the global programme of gene expression underlying SM-164 resistance in MDA-MB-231 cells and identified differentially expressed genes in SM-164-resistant and -sensitive MDA-MB-231 cells. SCID mice with MDA-MB-231 xenograft tumors were treated with 5 mg/kg of SM-164 intravenously for 5 days/week for 2 weeks. SM-164-regressed MDA-MB-231 tumors regrew after treatment ended. Tumor cells from these regrown MDA-MB-231 tumors were isolated and total RNAs were prepared for microarray analysis.

2012-03-01 | E-GEOD-33827 | biostudies-arrayexpress

Expression data from MDA-MB-231 parental and xenograft tumor cells treated with Smac mimetic SM-164.

Project description:Small-molecule Smac mimetics target inhibitor of apoptosis (IAP) proteins to induce TNFα-dependent apoptosis in cancer cells and several Smac mimetics have been advanced into clinical development as a new class of anticancer drugs. However, preclinical studies have shown that only a small subset of cancer cell lines are sensitive to Smac mimetics used as single agents and these cell lines are at risk of developing drug resistance to Smac mimetics. Thus, it is important to understand the molecular mechanisms underlying intrinsic and acquired resistance of cancer cells to Smac mimetics in order to develop effective therapeutic strategies to overcome or prevent Smac mimetic resistance. We established Smac mimetic resistant sublines derived from MDA-MB-231 breast cancer cells, which exhibit exquisite sensitivity to the Smac mimetic SM-164, and used microarrays to detail the global programme of gene expression underlying SM-164 resistance in MDA-MB-231 cells and identified differentially expressed genes in SM-164-resistant and -sensitive MDA-MB-231 cells.

2012-03-01 | GSE33827 | GEO

Tang2019 - Pharmacology modelling of AURKB and ZAK interaction in TNBC

Project description:Aurora Kinase B and ZAK interaction model Equivalent of the stochastic model used in "Network pharmacology model predicts combined Aurora B and ZAK inhibition in MDA-MB-231 breast cancer cells" by Tang et. al. 2018. The only difference is cell division and partitioning of the components, which are available in the original model for SGNS2.

2024-09-02 | BIOMD0000000940 | BioModels

MiRNA-based on genome-wide maps in MDA-MB-231 cells treated with or without Tanshinone IIA (TSA).

Project description:Analysis of MDA-MB-231 cells following TSA treatment or not. TSA regulates various miRNA expression in MDA-MB-231 cells.Results provide insight into the role of miRNAs-involved mechanisms underlying TSA-mediated effects on breast cancer stemness.

2022-01-01 | GSE156155 | GEO

Genome-wide maps in MDA-MB-231 cells treated with or without HET0016 (5 μM).

Project description:Analysis of MDA-MB-231 cells following HET0016 treatment or not. HET0016 regulates various mRNA expression in MDA-MB-231 cells.Results provide insight into the role of mRNAs-involved mechanisms underlying HET0016-mediated effects on breast cancer stemness.

2021-12-29 | GSE163954 | GEO

Gene expression profile in breast cancer cells

Project description:We report the gene expression patterns in MDA-MB-231 (a line selected for low metastatic ability), MDA-MB-231-1833 (its bone-tropic metastatic derivative line), MDA-MB-231p27CK-DD (a phosphomimetic cell line), MDA-MB-231-1833shp27 (p27 knockdown cell line), MDA-MB-231-1833PF1502 (PI3K inhibitor treatment). It shows that the gene expression pattern are regulated in a p27 phosphorylation-dependent manner.

2019-03-19 | GSE112445 | GEO

Proteomics analysis of Polyphyllin D-treated triple-negative breast cancer cells reveal the anticancer mechanisms of Polyphyllin D

Project description:Polyphyllin D (PD) is the active component from an Asian traditional medicinal herb Paris polyphylla, and has been found to hold significant anticancer activity in vivo or in vitro. However, the mechanism through which PD exerts its anticancer effects in triple-negative breast cancer (TNBC) remains unclear. Our study was presented to evaluate the anticancer effect and the potential mechanisms of PD in two TNBC cell lines, namely BT-549 and MBA-MB-231. Through comprehensively comparing the liquid chromatography-tandem mass spectrometry (LC-MS/MS) data of PD-treated and -untreated BT-549 and MBA-MB-231 cells, we found PD could activate oxidative phosphorylation pathway in BT-549 cells and inhibit spliceosome function in MDA-MB-231 cells, suggesting that the anticancer effect of PD may be cell type-specificity dependent. Moreover, we found that nodal modulator 2/3 (NOMO2/3) were down-regulated both in PD-treated BT-549 and MBA-MB-231 cells, suggesting NOMO2/3 may be the potential target of PD. Whether NOMO2/3 are the upstream modulators of oxidative phosphorylation pathway and Spliceosome need further validation. In conclusion, a comprehensive proteomics study was performed on PD-treated or untreated TNBC cells, revealing the anticancer mechanisms of PD.

2023-03-20 | PXD040990 |

Polyploid cancer cells reveal signatures of chemotherapy relapse [scRNA-seq]

Project description:Treatment of PC3 and MDA-MB-231 cell lines with sublethal doses of docetaxel or cisplatin in vitro resulted in induction of polyploid cancer cells. Single cell copy RNA-sequencing was conducted to understand resistance of polyploid cancer cells to chemotherapy.

2024-09-13 | GSE270568 | GEO

Polyploid cancer cells reveal signatures of chemotherapy relapse [scDNA-seq]

Project description:Treatment of PC3 and MDA-MB-231 cell lines with sublethal doses of docetaxel or cisplatin in vitro resulted in induction of polyploid cancer cells. Single cell copy number profiling was conducted to understand resistance of polyploid cancer cells to chemotherapy.

2024-09-13 | GSE270567 | GEO

LncRNA Uc003xsl.1 Activates of NF-κB/IL8 Axis to Promotes Triple-negative Breast Cancer Progression via A Decoy Role to NKRF [lnc231]

Project description:To discover the potential drivers of TNBC metastasis, we established an in vivo model by injecting MDA-MB-231cells into the tail veins of mice. Then, the breast tumor cells that successfully grew into metastatic lung tumors were collected and expanded in vitro, followed by re-injected into the tail veins of mice for lung metastasis. After three rounds of selection, a highly metastatic subline, MDA-MB-231-P3, was established, and more frequent micro-metastasis was detected in MDA-MB-231-P3 groups than that of MDA-MB-231 groups when the lungs of mice were stained with hematoxylin and eosin (HE). The lncRNA profiles of MDA-MB-231 or MDA-MB-231-P3 cells were analyzed by lncRNA sequencing. A total of 267 lncRNAs in MDA-MB-231-P3 cells were upregulated more than 2-fold in comparison to the MDA-MB-231 cells.

2021-11-29 | GSE163900 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data